NEWSROOM

132 results have been found

Corporate
Investors
Products

2020
2019
2018
2017
2016

September 14, 2020

Grifols more committed than ever to its values and long-term vision six months into the pandemic

September 7, 2020

Grifols to acquire Alkahest to enhance discovery research and development to identify innovative therapies for age-related diseases based upon an understanding of the human plasma proteome

July 30, 2020

Grifols revenues grow 10.5% to EUR 2,677 million driven by the Bioscience Division

July 28, 2020

Grifols delivers first manufactured batches of its anti-SARS-CoV-2 hyperimmune globulin for clinical trials

July 27, 2020

Results of Grifols’ AMBAR clinical trial published in Alzheimer's & Dementia: The Journal of the Alzheimer’s Association

Content: footer-organization-info

The information contained on the Grifols worldwide website is not applicable to all countries. For specific information on the products and services available in your country, please select your country from the list included in the corresponding section. The purpose of this website is to provide information about Grifols' products and services, and it is not intended for, nor may it be construed to, promoting any products in countries in which they are not approved.